Reported about 2 months ago
Bavarian Nordic A/S saw a notable rise in its stock price following an announcement that it will fulfill a significant mpox vaccine order from Europe, leading the company to anticipate reaching the top end of its full-year revenue guidance. The Danish company, which produces the only mpox vaccine approved by both US and EU regulators, expects its vaccine-related sales to climb to 3 billion Danish kroner ($790 million) this year. The CEO stated that the company is prepared to increase production and potentially establish local manufacturing in Africa to address the ongoing mpox outbreak, which has recently been declared a global health emergency.
Source: YAHOO